NASDAQ:MDCO - The Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.00 -1.06 (-5.56 %)
(As of 12/18/2018 06:00 AM ET)
Previous Close$19.06
Today's Range$17.8550 - $19.22
52-Week Range$17.85 - $41.57
Volume1.33 million shs
Average Volume1.06 million shs
Market Capitalization$1.41 billion
P/E Ratio-2.14
Dividend YieldN/A
Beta1.03
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
Previous Symbol
CUSIP58468810
Phone973-290-6000

Debt

Debt-to-Equity Ratio31.23
Current Ratio2.41
Quick Ratio2.40

Price-To-Earnings

Trailing P/E Ratio-2.14
Forward P/E Ratio-6.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.79 million
Price / Sales29.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.34 per share
Price / Book52.94

Profitability

EPS (Most Recent Fiscal Year)($8.40)
Net Income$-708,370,000.00
Net Margins-668.93%
Return on Equity-1,477.75%
Return on Assets-39.49%

Miscellaneous

Employees170
Outstanding Shares73,860,000
Market Cap$1.41 billion
OptionableOptionable

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Thursday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.13. The company had revenue of ($3.30) million for the quarter, compared to analysts' expectations of $1.88 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 1,477.75%. The firm's quarterly revenue was down 141.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.19) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

9 Wall Street analysts have issued 1 year target prices for The Medicines' shares. Their predictions range from $25.00 to $85.00. On average, they anticipate The Medicines' stock price to reach $50.3750 in the next twelve months. This suggests a possible upside of 179.9% from the stock's current price. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

Media stories about MDCO stock have trended negative on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. The Medicines earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future.

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Dr. Clive A. Meanwell, CEO & Director (Age 60)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 53)
  • Mr. William B. O'Connor, Special Advisor to the Chief Exec. Officer (Age 59)
  • Mr. Christopher Visioli, CFO & Treasurer (Age 42)

Who are The Medicines' major shareholders?

The Medicines' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (9.05%), Vanguard Group Inc (9.05%), PointState Capital LP (3.97%), Iridian Asset Management LLC CT (2.55%) and Pinnacle Associates Ltd. (1.11%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.

Which major investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, HealthCor Management L.P., Iridian Asset Management LLC CT, Pinnacle Associates Ltd., Tekla Capital Management LLC, Elk Creek Partners LLC, United Services Automobile Association and TIAA CREF Investment Management LLC. Company insiders that have sold The Medicines company stock in the last year include Armin M Kessler, Clive Meanwell, Melvin K Spigelman and William Crouse. View Insider Buying and Selling for The Medicines.

Which major investors are buying The Medicines stock?

MDCO stock was purchased by a variety of institutional investors in the last quarter, including University of Notre Dame DU Lac, Federated Investors Inc. PA, Vanguard Group Inc, Vanguard Group Inc., FMR LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Panagora Asset Management Inc. and Bailard Inc.. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $18.00.

How big of a company is The Medicines?

The Medicines has a market capitalization of $1.41 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. The Medicines employs 170 workers across the globe.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  428 (Vote Outperform)
Underperform Votes:  312 (Vote Underperform)
Total Votes:  740
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel